J R Lee1, Z X He, H Dakik, M S Verani. 1. Section of Cardiology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA.
Abstract
BACKGROUND: There is scanty information on the angiographic and myocardial perfusion correlates of dobutamine-induced ST-segment elevation. METHODS AND RESULTS: We studied 39 patients who exhibited ST-segment elevation during dobutamine perfusion tomography and had recent coronary angiography performed (ie, within 3 months of the dobutamine study). Baseline characteristics, extent of coronary artery disease, relationship of Q waves to ST-segment elevation, ischemic burden, and angiographic findings were assessed. Twenty-nine patients (74%) had prior myocardial infarction, and 77% had abnormal Q waves at baseline. Ninety-three percent of patients had abnormal perfusion imaging. Eighty percent of patients had multivessel coronary artery disease. The left ventricular ejection fraction by contrast ventriculography was 35% +/- 7% (mean +/- SD), the perfusion defect size was 32% +/- 15%, and 73% of patients had some degree of myocardial ischemia. A predominance of ischemia (>50% reversibility) occurred in 38% of patients with Q waves and in 70% of those without Q waves. There was also good agreement between the site of ST-segment elevation and the site of ischemia by perfusion imaging (79%) and between the site of ST-segment elevation and the location of the vessel with significant coronary stenosis (95%). CONCLUSIONS: Patients with dobutamine-induced ST-segment elevation have a depressed left ventricular ejection fraction, a high frequency of multivessel disease, and markedly abnormal myocardial perfusion tomography. In patients with ST-segment elevation and abnormal Q waves, substantial scarring and superimposed ischemia coexist, whereas in patients without Q waves, ST-segment elevation usually denotes severe ischemia.
BACKGROUND: There is scanty information on the angiographic and myocardial perfusion correlates of dobutamine-induced ST-segment elevation. METHODS AND RESULTS: We studied 39 patients who exhibited ST-segment elevation during dobutamine perfusion tomography and had recent coronary angiography performed (ie, within 3 months of the dobutamine study). Baseline characteristics, extent of coronary artery disease, relationship of Q waves to ST-segment elevation, ischemic burden, and angiographic findings were assessed. Twenty-nine patients (74%) had prior myocardial infarction, and 77% had abnormal Q waves at baseline. Ninety-three percent of patients had abnormal perfusion imaging. Eighty percent of patients had multivessel coronary artery disease. The left ventricular ejection fraction by contrast ventriculography was 35% +/- 7% (mean +/- SD), the perfusion defect size was 32% +/- 15%, and 73% of patients had some degree of myocardial ischemia. A predominance of ischemia (>50% reversibility) occurred in 38% of patients with Q waves and in 70% of those without Q waves. There was also good agreement between the site of ST-segment elevation and the site of ischemia by perfusion imaging (79%) and between the site of ST-segment elevation and the location of the vessel with significant coronary stenosis (95%). CONCLUSIONS:Patients with dobutamine-induced ST-segment elevation have a depressed left ventricular ejection fraction, a high frequency of multivessel disease, and markedly abnormal myocardial perfusion tomography. In patients with ST-segment elevation and abnormal Q waves, substantial scarring and superimposed ischemia coexist, whereas in patients without Q waves, ST-segment elevation usually denotes severe ischemia.
Authors: A Margonato; C Ballarotto; F Bonetti; A Cappelletti; M Sciammarella; D Cianflone; S L Chierchia Journal: J Am Coll Cardiol Date: 1992-04 Impact factor: 24.094
Authors: A Elhendy; M L Geleijnse; J R Roelandt; R T van Domburg; J H Cornel; F J TenCate; J Postma-Tjoa; A E Reijs; G M el-Said; P M Fioretti Journal: Am J Cardiol Date: 1995-09-01 Impact factor: 2.778
Authors: A Lombardo; F Loperfido; F Pennestri; E Rossi; R Patrizi; G Cristinziani; G Catapano; A Maseri Journal: J Am Coll Cardiol Date: 1996-03-01 Impact factor: 24.094